Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Stopped early · Phase 3

Conditions studied: Wilson Disease

In brief

The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and safety will be evaluated during an optional 60-month Extension Period.

Key facts

Study ID

NCT03403205

Run by

Alexion Pharmaceuticals, Inc.

People needed

214

Starts

2018-02-22

Expected to finish

2023-06-30

Last updated by the study team

2024-06-17

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — New Haven, Connecticut, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Ann Arbor, Michigan, United States
• Research Site — Houston, Texas, United States
• Research Site — Seattle, Washington, United States
• Research Site — Adelaide, Australia
• Research Site — Concord, Australia
• Research Site — Parkville, Australia
• Research Site — Parkville, Australia
• Research Site — Graz, Austria
• Research Site — Innsbruck, Austria
• Research Site — Vienna, Austria
• Research Site — Toronto, Ontario, Canada
• Research Site — Prague, Czechia
• Research Site — Århus N, Denmark
• Research Site — Bron, France
• Research Site — Paris, France
• Research Site — Hamburg, Germany
• Research Site — Heidelberg, Germany
• Research Site — Leipzig, Germany
• Research Site — Hong Kong, Hong Kong
• Research Site — Budapest, Hungary
• Research Site — Jerusalem, Israel
• Research Site — Ramat Gan, Israel
• Research Site — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.